Verrica resubmits NDA for VP-102 (molluscum contagiosum) to FDA

Verrica Pharmaceuticals Inc.

Resubmitted the New Drug Application for VP-102 to the FDA on January 24, 2023.
VP-102 is intended for the treatment of molluscum contagiosum.
No additional details regarding the resubmission content or timeline were disclosed.

item 8.01

Verrica Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-013704

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.